Corindus Vascular Robotics Appoints Jeff Lemaster Chief Commercial Officer
October 20 2016 - 6:45AM
Business Wire
Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a
leading developer of precision vascular robotics, today announced
the appointment of Jeff Lemaster as Chief Commercial Officer.
Mr. Lemaster brings 20 years of commercial sales and marketing
experience in the cardiovascular medical device industry to
Corindus and has extensive global new product launch experience in
the areas of interventional cardiology and peripheral. He most
recently served as Global Vice President, Marketing of C.R. Bard,
Inc. [NYSE: BCR], a leading multinational developer, manufacturer
and marketer of innovative, life-enhancing medical technologies. He
has a proven track record of commercial success having held senior
sales and marketing leadership positions at C.R. Bard, ACIST
Medical Systems and Boston Scientific Corporation (NYSE: BSX).
As Chief Commercial Officer at Corindus, Mr. Lemaster will lead
and execute revenue and commercial strategy to drive growth and
market adoption globally.
"I am delighted to welcome Jeff to Corindus, and we look forward
to his future contributions. His extensive commercial experience,
particularly in the interventional and peripheral arena, will
enable us to build and sustain strong robotic programs that benefit
our customers and their patients," said Corindus CEO, Mark J.
Toland.
"I look forward to working with the Corindus team and the
broader interventional community to build robotic programs that
transform the way we treat patients while protecting cath lab
teams," said Mr. Lemaster.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader
in robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to both percutaneous coronary intervention (PCI) and
peripheral vascular intervention. During the procedure, the
interventional cardiologist sits at a radiation-shielded
workstation to advance stents and guidewires with
millimeter-by-millimeter precision. The workstation allows the
physician greater control and the freedom from wearing heavy lead
protective equipment that causes musculoskeletal injuries. With the
CorPath System, Corindus Vascular Robotics brings robotic precision
to complex, radial, coronary and peripheral procedures to help
optimize clinical outcomes and minimize the costs associated with
complications of improper stent placement with manual procedures.
Corindus stands behind its product with its unique $1,000 hospital
credit "One Stent Program." For additional information, visit
www.corindus.com, and follow @CorindusInc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161020005061/en/
Corindus Vascular Robotics, Inc.Media Contacts:Kate Stanton,
508-653-3335 ext. 200kate.stanton@corindus.comorYuliya Kutuzava,
203-504-8230 ext. 131corindus@knbpr.comorInvestor Contact:Lynn
Pieper Lewis, 415-937-5402ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Apr 2023 to Apr 2024